A vaccinia virus encoding the human sodium iodide symporter facilitates long-term image monitoring of virotherapy and targeted radiotherapy of pancreatic cancer Journal Article
| Authors: | Haddad, D.; Zanzonico, P. B.; Carlin, S.; Chen, C. H.; Chen, N. G.; Zhang, Q.; Yu, Y. A.; Longo, V.; Mojica, K.; Aguilar, R. J.; Szalay, A. A.; Fong, Y. |
| Article Title: | A vaccinia virus encoding the human sodium iodide symporter facilitates long-term image monitoring of virotherapy and targeted radiotherapy of pancreatic cancer |
| Abstract: | To assess therapeutic response and potential toxicity of oncolytic virotherapy, a noninvasive, deep-tissue imaging modality is needed. This study aimed to assess the feasibility, parameters, and determining factors of serial imaging and long-term monitoring of virotherapy and the therapeutic response of pancreatic cancer xenografts treated with a vaccinia virus carrying the human sodium iodide symporter GLV-1h153. Methods: Pancreatic cancer xenografts (PANC-1) in nude mice were treated systemically or intratumorally with GLV-1h153 and serially imaged using 124I PET at 1, 2, 3, and 5 wk after viral injection. Signal intensity was compared with tumor therapeutic response and optical imaging, and tumors were histologically analyzed for morphology and the presence of virus. Autoradiography was performed using technetium-pertechnetate and γ-scintigraphy to assess determining factors for radiouptake in tumors. Finally, the enhanced therapeutic effect of combination therapy with GLV-1h153 and systemic radioiodine was assessed. Results: GLV-1h153 successfully facilitated serial long-term imaging of virotherapy, with PET signal intensity correlating to tumor response. GLV-1h153 colonization of tumors mediated radioiodine uptake at potentially therapeutic doses. Successful radiouptake required the presence of virus, adequate blood flow, and viable tissue, whereas loss of signal intensity was linked to tumor death and necrosis. Finally, combining systemically administered GLV- 1h153 and 131I led to enhanced tumor kill when compared with virus or 131I alone (P < 0.01). Conclusion: GLV-1h153 is a promising oncolytic agent for the treatment, long-term imaging, and monitoring of therapeutic response in a xenograft model of pancreatic cancer. GLV-1h153 provided insight into tumor biologic activity and facilitated enhanced tumor kill when combined with systemic targeted radiotherapy. These results warrant further investigation into parameters and potential synergistic effects of combination therapy. Copyright © 2012 by the Society of Nuclear Medicine and Molecular Imaging, Inc. |
| Keywords: | controlled study; treatment outcome; unclassified drug; human cell; nonhuman; cancer radiotherapy; pancreas cancer; pancreatic neoplasms; positron emission tomography; animal cell; mouse; animals; mice; image analysis; animal experiment; animal model; molecular imaging; cell line, tumor; morphology; time factors; feasibility study; immunoglobulin g; iodine 131; radioactive iodine; iodine radioisotopes; feasibility studies; tumor burden; positron-emission tomography; oncolytic virus; oncolytic virotherapy; vaccinia virus; single drug dose; iodine 124; pancreatic cancer; image processing; image display; autoradiography; virotherapy; vaccinia; oncolytic; sodium iodide symporter; optical imaging; glv 1h153; pertechnetic acid tc 99m; symporters; radiotherapy, image-guided; targeted radiotherapy; gamma scintigraphy |
| Journal Title: | Journal of Nuclear Medicine |
| Volume: | 53 |
| Issue: | 12 |
| ISSN: | 0161-5505 |
| Publisher: | Society of Nuclear Medicine |
| Date Published: | 2012-12-01 |
| Start Page: | 1933 |
| End Page: | 1942 |
| Language: | English |
| DOI: | 10.2967/jnumed.112.105056 |
| PROVIDER: | scopus |
| PUBMED: | 23139088 |
| PMCID: | PMC6386167 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 2 January 2013" - "CODEN: JNMEA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work